Active Ingredient History
Zonisamide is an antiseizure drug chemically classified as a sulfonamide and unrelated to other antiseizure agents. The precise mechanism by which zonisamide exerts its antiseizure effect is unknown, although it is believed that the drug blocks sodium and calcium channels, which leads to the suppression of neuronal hypersynchronization (i.e. convulsions). Sonisamide has also been found to potentiate dopaminergic and serotonergic neurotransmission but does not appear to potentiate syanptic activity by GABA (gamma amino butyric acid). Zonisamide binds to sodium channels and voltage sensitive calcium channels, which suppresses neuronal depolarization and hypersynchronization. Zonisamide also inhibits carbonic anhydrase to a weaker extent, but such an effect is not thought to contribute substantially to the drug's anticonvulsant activity. Zonisamide is approved in the United States, United Kingdom, and Australia for adjunctive treatment of partial seizures in adults and in Japan for both adjunctive and monotherapy for partial seizures (simple, complex, secondarily generalized), generalized (tonic, tonic-clonic (grand mal), and atypical absence) and combined seizures. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Alcohol-Induced Disorders (Phase 2)
Alcoholism (Phase 4)
Bipolar Disorder (Phase 4)
Cocaine-Related Disorders (Phase 1/Phase 2)
Drug Resistant Epilepsy (Phase 4)
Dyskinesias (Phase 4)
Dystonia (Phase 3)
Epilepsies, Partial (Phase 4)
Epilepsy ()
Epilepsy, Complex Partial (Phase 3)
Essential Tremor (Phase 2)
Fibromyalgia (Phase 4)
Glioma (Phase 4)
Healthy Volunteers (Phase 1)
Hearing Loss, Noise-Induced (Phase 2)
Intellectual Disability (Phase 4)
Migraine Disorders (Phase 4)
Obesity (Phase 4)
Parkinson Disease (Phase 4)
Parkinsonian Disorders (Phase 4)
Psychotic Disorders (Phase 3)
Schizophrenia (Phase 3)
Seizures (Phase 4)
Sleep Apnea, Obstructive (Phase 2)
Sleep Apnea Syndromes (Phase 2)
Smoking Cessation (Phase 3)
Stress Disorders, Post-Traumatic (Phase 2)
Tobacco Use Disorder (Phase 1/Phase 2)
Weight Gain (Phase 3)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue